← Back to “About Us” Index

Rick Kingston, PharmD

Share

Rick Kingston, PharmDDr. Kingston brings 28 years professional experience to SafetyCall International in the areas of clinical toxicology and pharmacology, poison control, product post-market surveillance, and drug and dietary supplement safety. Previously, Dr. Kingston served as vice president and co-founder of poison center services for PROSAR Inc. as well as co-founder and former Director of the Minnesota Regional Poison Center and its affiliated industry toxicology programs at St. Paul Ramsey Medical Center, in St. Paul, MN. He has 23 years of critical care toxicology experience gained from practice in a university-affiliated Level One Trauma Center. He holds a joint academic appointment with the University of Minnesota at the rank of full Professor in the Department of Experimental and Clinical Pharmacology within the College of Pharmacy. Dr. Kingston completed his BS in Pharmacy degree at the University of New Mexico, his Doctorate in Clinical Pharmacy at the University of Minnesota, and a Post-Doctoral Fellowship in clinical toxicology and pharmacokinetics at Ramsey Medical Center and the University of Minnesota. In his academic capacity he serves in multiple areas related to his practice focus of “clinical toxicology and product safety.”

Dr. Kingston continues academic and scholarly activities where his research efforts have resulted in 40 scientific abstracts, 20 publications, 18 confidential peer-reviewed technical papers, and 3 textbook chapters. He is co-editor for an upcoming text on the clinical pharmacology and toxicology of dietary supplements. He is a frequent invited lecturer and/or visiting professor where he has delivered more than 200 presentations in national and international venues related to his practice. His research and practice interests coincide with SafetyCall International initiatives for corporate clients and include a focus on injury prevention, the epidemiology of toxicology related incident data, product safety and related regulatory affairs, and specific advances in the clinical management of patients being treated or evaluated for drug, toxin or consumer product exposures.